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5Abstract
6The study of host AMP-activated protein kinase (AMPK) activation during Leishmania infection imposes
7distinct types of techniques to measure protein expression and activation, as well as to quantify, at
8transcription and translational levels, its downstream targets. The investigation of host AMPK protein
9modulation during Leishmania infection should primarily be assessed during in vitro infections using as a
10host murine bone marrow-derived macrophages (BMMos). The infection outcome is assessed measuring
11the percentage of infected cells in the context of BMMos. To evaluate AMPK activity during infection, the
12expression of AMPK-phosphorylated at Thr172 as well as the transcription and translational levels of its
13downstream targets are evaluated by quantitative PCR and immunoblotting. The modulation of AMPK
14activity in vivo is determined specifically in sorted splenic macrophages harboring Leishmania parasites
15recovered from infected mice using fluorescent-labeled parasites in the infectious inocolum. The modula-
16tion of AMPK activity was assessed by AMPK activators and inhibitors and also using AMPK, SIRT1, or
17LKB1-KO mice models. The infection outcome in BMMos and in vivo was further determined using these
18two different approaches. To finally understand the metabolic impact of AMPK during infection, in vitro
19metabolic assays in infected BMMos were measured in the bioenergetic profile using an extracellular flux
20analyzer.
21Key words Leishmania, AMPK, Bioenergetic profile, Extracellular flux analyzer, AMPK activators and
22inhibitors, SIRT1, Mitochondria, Cell metabolism, Macrophages
231 Introduction
24Leishmania spp. is the causative agent of leishmaniasis, a neglected
25tropical disease transmitted by the bite of an infected female sand fly
26[1]. These parasites are mainly phagocyted by macrophages being
27able to subvert their intracellular signaling pathways and compete
28for similar resources [2–4]. A key question in the context of host-
29pathogen interactions is how pathogens survive in a hostile envi-
30ronment and how they hijack host machinery for their own benefit.
31To address AMPK signaling during Leishmania infection, bone
32marrow precursors are differentiated in vitro with macrophage
33colony-stimulating factor (M-CSF) and used as a target cell for
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34infection (Subheading 3.1). This differentiation procedure leads to
35a higher yield and reproducibility, being these bone marrow-
36derived macrophages (BMMos) commonly considered as a model
37for the role of resident macrophages [5]. The infection is per-
38formed at early (6 h post-infection) and at later time points of
39infection (18 h post-infection) to acquire a dynamic profile of the
40infection process. The level of infected cells was obtained through
41the infection of BMMos with CFSE-labeled parasites being the
42percentage of CFSE+ or eFluor670+ cells, obtained by FACS analy-
43sis, a direct measurement of parasites internalization [6, 7] (Sub-
44heading 3.1). A direct analysis of AMPK activation in a context of
45infection is addressed through immunoblotting of total and phos-
46phorylated Thr172 both in infected BMMos (Subheading 3.1) and
47in sorted infected splenic macrophages (Subheading 3.2). The
48modulation of AMPK activity during infection can be obtained
49establishing a pharmacological approach where an AMPK activator
50(AICAR) and/or inhibitor (compound C) can be used isolated or
51in combination, as was described by us and by other authors in
52different contexts of infection [7–9]. The establishment on an
53in vivo infection (Subheading 3.2) using myeloid-restricted
54(Mac)-AMPK, SIRT1, or LKB1 KO mice (Subheading 3.3) is
55imperative to evaluate the impact of AMPK for the infection out-
56come in Leishmania-parasitized organs. SIRT1 has been investi-
57gated in different contexts as a potential modulator of AMPK
58activation. On one hand SIRT1 protein has been described as an
59upstream activator of AMPK through LKB1 deacetylation and on
60the other hand has been considered a downstream target of AMPK,
61becoming activated by the increase levels of NAD+ [10–13]. The
62parasite load in Leishmania-parasitized organs is determined ulti-
63mately by real-time quantitative PCR (qRT-PCR) (Subheading
643.2) [7, 14]. The metabolic impact of AMPK during Leishmania
65infection can be finally addressed using the extracellular flux ana-
66lyzer in infected BMMos. Host bioenergetic profile at real time is
67traced at basal conditions and in response to distinct pharmacolog-
68ical agents, which allow the quantification of metabolic parameters
69as extracellular acidification rate (ECAR), oxygen consumption rate
70(OCR), spare respiratory capacity (SRC), and glycolytic capacity
71(Subheading 3.3). Overall, with these techniques we could trace
72the activation of host AMPK network during Leishmania infection
73and the impact on parasite survival.
742 Materials
2.1 Animals
and Parasites
751. Myeloid cell-specific (Mac)-Sirt1 KO mice, Mac-AMPKα1
76KO, Mac-LKB1 KO on C57BL/6 genetic background, and
77the respective littermate lox control (Lysozyme M-Cre+/+
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78Sirt1flox/flox) mice. All animals used in experiments are aged
79from 6 to 12 weeks.
802. L. infantum (MHOM/MA/67/ITMAP-263) promastigotes.
81
2.2 Culture Reagents 821. Macrophage medium: DMEM, 4.5 g/L glucose, 20 mM
83HEPES, 10% (v/v) heat-inactivated fetal bovine serum (FBS),
842 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml
85streptomycin.
862. Leishmaniamedium: RPMI 1640, 20 mMHEPES, 10% (v/v)
87heat-inactivated FBS, 2 mM L-glutamine, 100 U/ml penicillin,
88100 mg/ml streptomycin.
893. Macrophage growth factor: 100 μg/ml M-CSF.
904. XF medium: unbuffered DMEM, 4.5 g/L glucose, 2% (v/v)
91FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml
92streptomycin.
935. Carboxyfluorescein succinimidyl ester (CFSE, FITC) and
94eFluor670 (APC): 5 mM stock solution.
956. AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide).
967. Compound C (also known as Dorsomorphin).
978. SRT1720.
98
2.3 FACS Staining 991. DMEM-EDTA: DMEM, 50 mM EDTA.
1002. Phosphate buffer saline (PBS): 145 mM NaCl, 2.7 mM KCl,
1011.5 mM KH2PO4, 8 mM Na2HPO4 · 2H2O, pH 7.
1023. PBS-FBS: PBS, 2% (v/v) FBS.
1034. Probes: 14.6 mM 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)
104amino]-2-deoxy-D-glucose (2-NBDG) and 1 mg/ml
1057-Aminoactinomycin D (7-AAD).
106
2.4 Antibodies 1071. FACS: anti-mouse monoclonal antibodies—anti-CD11b-PE
108(M1/70), anti-Ly6C-PerCP/Cy5.5 (HK1.4), anti-Ly6G-
109Pacific Blue (1A8), and anti-F4/80-PerCP-Cy5.5 (BM8).
1102. Cell magnetic separation: CD3ε and CD19 microbeads.
1113. PBS-EDTA buffer: PBS, 0.5% (w/v) BSA (bovine serum albu-
112min), 2 mM EDTA, pH 7.2.
1134. Immunoblot: total AMPKα (23A3), AMPKα phosphorylated
114at Thr172, total SIRT1 (H-300), total PGC1β (E-9), β-actin
115(C4), total PGC1α (4C1.3), and horseradish peroxidase-
116coupled secondary reagents.
117
2.5 Quantitative PCR
Analysis
1181. TRIzol reagent.
1192. Chloroform.
1203. Isopropanol.
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1214. Ethanol 75% (c/v) in H2O.
1225. H2O RNase free.
1236. RNeasy micro kit.
1247. QIAmp DNA micro kit.
1258. cDNA synthesis Kit.
1269. SYBR Green Supermix.
12710. Primers: R221 and R332 primers parasite load quantification
128and primers for real-time quantitative PCR listed in Table 1.
12911. DNazol.
130
2.6 Immunoblot 1311. Lysis buffer: 50 mM Tris-HCL, pH 7.4, 1% (v/v) Triton
132X-100, 150 mM NaCl, 10% (v/v) glycerol, 50 mM NaF,
1335 mM sodium pyrophosphate, 1 mM Na3VO4, 25 mM
134sodium-β-glycerophosphate, 1 mMDTT, 0.5 mM PMSF, pro-
135tease and phosphatase inhibitor cocktails.
1362. Dc protein assay with reagent S (Bio-Rad).
1373. SDS polyacrylamide gel 10% resolving gel buffer (4.5 mL):
1381.9 mL H2O, 1.7 mL 30% acrylamide, 1.3 mL Tris-HCL pH
1398.8, 50 μL of 10% SDS, 50 μL of 10% APS, 2 μL of TEMED.
140Stacking gel (3 mL): 2.1 mL of H2O, 500 μL of 30% acrylam-
141ide, 380 μL of 0.5 M Tris-HCL pH 6.8, 30 μL of 10% SDS,
14230 μL of 10% APS, 3 μL of TEMED.
1434. Transfer pack with nitrocellulose membrane.
1445. Western blot transfer system.
1456. Ponceau S.
1467. Block/diluent solutions: 10% (w/v) BSA, 0.05% (v/v)
147Tween 20.
1488. SuperSignal West Pico or West Dura chemiluminescent
149substrate.
1509. Striping solution I: 0.2 M glycine, 0.5 M NaCl, pH 2.8.
15110. Striping solution II: 0.5 M Acetic acid, 0.5 M NaCl, pH 2.5.
152
t:1 Table 1
List of primers used for real-time quantitative PCR (qRT-PCR)
Genes Forward sequence Reverse sequence
Accession
numbert:2
Ppargc1a AGCCGTGACCACTGACAACGAG GCTGCATGGTTCTGAGTGCTAAG NM_008904t:3
Slc2a4 ACATACCTGACAGGGCAAGG CGCCCTTAGTTGGTCAGAAG NM_009204t:4
RPS29 CACCCAGCAGACAGACAAACTG GCACTCATCGTAGCGTTCCA NM_009093t:5
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2.7 Equipment 1531. Gamma irradiator.
1542. Flow cytometer.
1553. Western blot transfer system.
1564. Microplate reader.
1575. Western blot detection system.
1586. Protein expression quantification software.
1597. Spectrophotometer.
1608. Real-time PCR thermal cycler.
1619. Magnetic cell separator system.
16210. Extracellular flux analyzer.
163
1643 Methods
3.1 Infection of Bone
Marrow-Derived
Macrophages
with L. infantum
3.1.1 Isolation
and Culture of Mouse
Bone Marrow-Derived
Macrophages
1651. Anesthetize mice through isoflurane inhalation and euthanize
166by cervical dislocation.
1672. Isolate the femurs and tibias of each mouse with a sterile scalp
168and scissor from the hind legs (see Note 1).
1693. Holding the femurs and the tibias with the help of a scissor, cut
170off with a scalpel each tip of the bones. Recover bone marrow
171precursors by flushing the bone marrow with 3–5 mL of
172ice-cold complete macrophage medium (per femur or tibia)
173with the help of a syringe and a 26 G needle.
1744. Centrifuge bone marrow cells at 300! g for 10min at 4 "C and
175resuspend in complete macrophage medium.
1765. Plate the bone marrow precursor cells without counting in a
17775 cm2 culture flask in a volume of 15 mL of complete macro-
178phage medium. Incubate at 37 "C with 5% CO2 for 4–6 h.
1796. Discard the adherent cells (differentiated macrophages from
180the stroma), and recover the bone marrow precursors present
181in the supernatant. Count with trypan blue and seed the bone
182marrow precursors in macrophage medium with 20 ng/ml of
183M-CSF at a proportion of 1! 105 cells in 200 μL of medium in
18496-well plates, 2 ! 105 cells in 400 μL of medium in 24-well
185plates, and 1 ! 106 cells in 2 mL of medium in 6-well plates.
1867. RenewM-CSF growth factor at day 4 of culture in each well by
187adding 20 ng/ml ofM-CSF.Macrophages acquired a definitive
188differentiation status at day 7 of culture, being defined as bone
189marrow-derived macrophages (BMMos) (see Note 2).
190
3.1.2 Labeling
of Promastigotes
and Infection Assay
1911. Start a 5 mL culture of L. infantum promastigotes at a concen-
192tration of 1 ! 106 promastigotes/ml of Leishmania medium
193(see Note 3).
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1942. At day 5 of growth, wash L. infantum promastigotes twice with
1955 mL of PBS and resuspend the parasites in 1 mL of PBS.
196Count the parasites by diluting 1/10 in 2% (v/v) glutaralde-
197hyde that fix the parasites. Dilute the Leishmania culture to
1986 ! 107 promastigotes in 1 mL of PBS.
1993. Label with 5 μM CFSE for 10 min or 1 μM eFluor670 for
2005min at 37 "C followed by 5 min incubation at 4 "C to stop the
201reaction (see Note 4).
2024. Wash the parasites twice with 5 mL of PBS, and resuspend in
2031 mL of Leishmania medium before proceeding to infections.
2045. Count the parasites by diluting 1/10 in 2% (v/v) glutaralde-
205hyde and infect 7-day differentiated BMMos with labeled and
206unlabeled L. infantum promastigotes at a 1:10 ratio.
2076. Irradiate 6 ! 107 promastigotes suspended in 1 mL of Leish-
208mania culture medium at 3000 Gy. Perform control experi-
209ments with those irradiated parasites using the previous
210co-culture ratio.
2117. After 4 h of incubation, remove the medium of each well. Wash
212the cells, at least twice, with macrophage culture medium
213pipetting up and down several times.
2148. For each round of washing, observe under the microscope if
215the parasites are still present in the supernatant. Repeat the
216washing procedure until the complete removal of
217non-internalized parasites.
2189. Detach BMMos after 6 and 18 h post-infection. Remove the
219macrophage medium and add an equivalent volume of
220DMEM-EDTA solution. Wait 5 min at room temperature,
221and recover the BMMos by pipetting up and down several
222times.
22310. Centrifuge at 300 ! g for 10 min at room temperature.
22411. Resuspend BMMos in 200 μL of PBS-2%FBS solution, and
225incubate for 15 min at room temperature with 7-AAD at 1 μg/
226ml.
22712. Transfer the cells to the cytometer tubes. Acquire the samples
228in a flow cytometer.
22913. In the cytometer adopt the following gate strategy: exclude the
230death cells that are stained positively to 7-AAD. In the viable
231population (7-AAD#), gate the cells that stained positively to
232eFluor670 (eFluor670+) or CFSE (CFSE+).
23314. Obtain the percentage of infected cells by the % of CFSE+ or
234eFluor670+ cells. Determine the cell viability by the percentage
235of negative 7-AAD stained cells (see Note 5).
236
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3.2 Infection of Mice
with L. infantum
and Sorting of Infected
Splenic Macrophages
3.2.1 In Vivo Infection
2371. Infect mice intraperitoneally, using a 26 G needle, with 1! 108
238CFSE-labeled L. infantum promastigotes resuspended in
239200 μL of sterile PBS.
240
3.2.2 Parasite Load
Quantification
2411. At 10 days post-infection, anesthetize mice through isoflurane
242inhalation and euthanize by cervical dislocation. Remove and
243weigh spleen and liver. Transfer both organs to a 70 μm mesh
244cell strainer, within a small petri dish, and use the syringe
245plunger to process the organs to generate a single cell suspen-
246sion. Centrifuge at 300 ! g for 10 min at 4 "C, and resuspend
247in 5 mL of complete macrophage medium.
2482. Extract DNA from 10 mg of spleen and liver (single cell sus-
249pensions) or 3 ! 106 bone marrow cells by DNazol, according
250to the manufacturer instructions. Dissolve DNA in 100 μL of
251nuclease-free water. Quantify the total DNA in a NanoDrop
252spectrophotometer and prepare a twofold serial concentrations
253dilution adjusted for each tissue.
2543. Quantify Leishmania infantumDNA by qPCR using 1000 nM
255of R223 and 500 nM of R333 primers for the small subunit
256rRNA (SSUrRNA) [15]. As a template use 400 ng of total
257DNA in 20 μL of reaction with SYBR Green Supermix, accord-
258ing to the manufacturer’s instructions.
2594. Perform a touchdown qPCR in Bio-RadMy Cycler iQ5, with a
260final annealing temperature of 65 "C [16]. The denaturation
261temperature is at 94 "C (5 s) and synthesis at 72 "C (10 s) with
26230 cycles (see Note 6).
2635. Extrapolate CTs from a standard curve constructed previously
264with a serial dilutions of L. infantum DNA (strain MHOM/
265MA/67/ITMAP-263) diluted in host DNA (from spleen of
266naı¨ve mice). Calculate then Leishmania content expressed by
267parasites/μg of DNA (see Note 7).
268
3.2.3 Sorting of Infected
Splenic Macrophages
2691. Euthanize naı¨ve and CFSE-L. infantum promastigote infected
270mice at 18 or 48 h post-infection. Collect the spleens into a
271falcon with 5 mL of macrophage culture medium.
2722. Process the organs as step 2 in Subheading 3.2.1. Determine
273the cell number.
2743. Wash the cells twice with 5 mL PBS. Pipette off supernatant
275completely and resuspend cell pellet in 80 μL of PBS-EDTA
276buffer per 107 cells.
2774. Deplete splenic T and B lymphocytes using CD3ε and CD19
278microbeads coupled with depletion columns using a magnetic
279cell isolation separator.
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2805. Label the remaining cell suspension with 2 μg/ml anti-
281CD11b-PE, anti-Ly6C-PerCP/Cy5.5 and anti-Ly6G-Pacific
282Blue diluted in 25 μL of PBS-FBS solution for 30 min at 4 "C
283in the dark.
2846. Wash the cells twice with 200 μL of PBS-FBS solution, and
285resuspend the cell pellet in 200 μL of PBS-FBS solution. Trans-
286fer the cell suspension to the cytometer tubes.
2877. Sort the cells according to the surface expression of
288CD11b+Ly6Cint/highLy6Glow and CFSE expression gated on
289infected (CFSE+CD11b+Ly6Cint/highLy6Glow) or bystander
290(CFSE#CD11b+Ly6Cint/highLy6Glow) splenic macrophages.
291As a control, sort CD11b+Ly6Cint/highLy6Glow cells from the
292spleen of non-infected mice. The purity of the separation
293should be higher than 90%.
2948. Count the cells obtained after the sorting assay using trypan
295blue to exclude dead cells.
2969. Sorted splenic macrophages are rinse with PBS by centrifuga-
297tion at 300 ! g for 10 min at 4 "C.
29810. Resuspend 1 ! 105 sorted macrophages in 350 μL of RLT
299buffer with 7 μL of 2-mercaptoethanol, and isolate RNA
300according to RNeasy micro kit manufacturer’s instructions.
30111. Analyze the transcription levels of Ppargc1a (PGC-1α) and
302Slc2a4 (GLUT4) by qPCR using RPS29 as
303housekeeping gene.
30412. Resuspend 1 ! 106 sorted macrophages in ice-cold lysis buffer
305for 30 min at 4 "C with shaking. The supernatant is recovered
306after centrifugation at 17,000 ! g during 20 min at 4 "C.
30713. Analyze AMPK activation by immunoblot using the experi-
308mental procedure described in Chapter 27 (see Note 8).
309
3.3 Modulation
of AMPK in a Context
of Host-L. infantum
interaction
3.3.1 Modulation
of AMPK Activity During
In Vivo L. infantum
Infection
3101. Infect KO mouse models (Mac-Sirt1 KO mice, Mac-AMPKα1
311KO, Mac-LKB1) and the respective littermate lox controls, as
312described in Subheading 3.2.
3132. Evaluate the parasite load by qPCR as described in
314Subheading 3.2.
315
3.3.2 Modulation
of AMPK Activity in In Vitro
L. infantum-Infected
BMMos
3161. Treat BMMos, from WT, Mac-SIRT1 KO, Mac-AMPK KO,
317and Mac-LKB1 KO mice, previously infected with CFSE or
318eFluor670-L. infantum promastigotes, at 6 h post-infection
319with 440 μM AICAR, 440 μM AICAR, and 5 μM compound
320C, 1 μM SRT1720 or left untreated (see Note 9).
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3212. After 24 h of infection, detach BMMos by using the DMEM-
322EDTA solution and centrifuge at 300 ! g for 10 min at room
323temperature.
3243. Resuspend cells in 200 μL of PBS-2%FBS solution and incu-
325bate for 15 min at room temperature with 7-AAD at 1 μg/ml.
3264. Evaluate the infection rate as described in the Subheading 3.1.
327
3.3.3 In Vitro Metabolic
Assays of Infected Bone
Marrow Macrophages
3281. Collect bone marrow precursors as described in the Subhead-
329ing 3.1. Perform the 7-day differentiation process in 75 cm2
330culture flasks.
3312. After 7 days in culture, scrap the cells and seed BMMo at
3322! 105 cells/well in 400 μL of complete macrophage medium
333in XF-24 cell culture plates. Let the cells to adhere during an
334overnight period (see Note 10).
3353. This procedure warrants a homogeneous distribution of the
336cells under the XF-24 plate surface, decreasing the variability
337among wells.
3384. After an overnight period, infect the cells with irradiated or not
339L. infantum promastigotes at a 1:10 ratio, during 6 and 18 h.
3405. One hour before the defined times of infection, wash the cells
341with pre-warmed XF medium. In the final wash, add 200 μL of
342XF medium to each well, and incubate for an hour at 37 "C
343without CO2.
3446. Determine the real-time measurement of bioenergetic profile
345(eight wells per condition), oxygen consumption rate (OCR),
346and extracellular acidification rate (ECAR), under basal condi-
347tions and in response to oligomycin (1 μM), fluoro-carbonyl
348cyanide phenylhydrazone (FCCP—1 μM), rotenone (1 μM),
349and antimycin A (1 μM), using an extracellular flux analyzer, at
3506 and 18 h post-infection (Fig. 1).
Fig. 1 A representative image of the real-time measurement of oxygen consumption rate (OCR) and the
extracellular acidification rate (ECAR) in uninfected and infected BMMo. The different bioenergetic profiles
are obtained under basal conditions and in response to oligomycin (1 μM), fluoro-carbonyl cyanide phenyl-
hydrazone (FCCP—1 μM), rotenone (1 μM), and antimycin A (1 μM), using an XF-24 Extracellular Flux Analyzer
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3517. Obtain the non-mitochondrial respiration by subtracting the
352rotenone/antimycin A values. Calculate the spare respiratory
353capacity (SRC) by subtracting FCCP from basal OCR values,
354and define the glycolytic capacity as the variation between
355oligomycin and basal ECAR values. Normalize the values for
356all the conditions in relation to the protein content.
357
3584 Notes
3591. To maintain aseptic conditions and to easily remove the sur-
360rounding tissue, collect the femurs and tibias into alcohol
361solution for few seconds transferring afterward to DMEM
362medium.
3632. Determine the purity of the macrophage culture by quantifying
364by flow cytometry the percentage of the cells expressing simul-
365taneously the two surface markers CD11b and F4/80, which
366should be superior to 90%.
3673. Maintain a cloned line of virulent L. infantum (MHOM/MA/
36867/ITMAP-263) by weekly subpassages at 26 "C in Leish-
369mania medium. Use L. infantum promastigotes under four
370to ten passages in all the experiments.
3714. eFluor 670 has a peak emission at 670 nm being detected with
372a 660/20 band-pass filter (equivalent to APC, Alexa Fluor™
373647, or eFluor™ 660) while CFSE peak emission of 521 nm
374being detected with a 530/30 nm band-pass emission filter
375(equivalent to GFP or FITC). Given that both dyes display
376similar results, the choice of labeling dye relates to the dispon-
377ibility of the flow cytometry detectors and possibility to multi-
378color flow cytometry.
3795. Giemsa staining is an alternative procedure to determine the
380percentage of infected cells. Upon step 8, Subheading 3.1.2,
381remove the macrophage medium and wash BMMos with 1 mL
382of PBS. Add 1 mL of 1% (v/v) of paraformaldehyde for 20 min.
383Rinse twice with 1 mL of PBS and add 1 mL of Giemsa stain
384previously diluted 1:20 in deionized water. Incubate for 30 min
385and rinse with deionized water. Air dry and count the infected
386cells and the number of intracellular parasites in a microscope at
387a 400! magnification. Cell nucleus and the parasites acquire a
388purple coloration. The volumes given consider an infection
389protocol for 2 ! 105 BMMos in 400 μL of medium in
39024-well plates. Up or downscale accordingly to the chosen
391infection protocol.
3926. Whenever the qPCR gave a positive (with the expected melting
393curve) but unquantifiable value or a doubtable specific product
394(aberrant melting curve), perform a nested PCR [17] that has a
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395higher sensitivity (0.01 parasites) than the qPCR (0.6 parasites)
396to confirm the positivity of the quantitative result. For the first
397amplification reaction, use 300 nM of R221 and R332 primers
398[17]. For the second reaction, use 10 μL of the first PCR
399product diluted 1:40, which will serve as a template with the
400same R223 and R333 primers (300 nM and 150 nM, respec-
401tively) used for the qPCR.
4027. As alternatives, the detection and quantification of L. infantum
403kinetoplastid DNA can be performed by TaqMan-based qPCR
404assay [18] or the parasite burden determined by limiting dilu-
405tion assay [19]. For the former, reaction mixtures are com-
406posed of ABI TaqMan PCR 2! (Applied Biosystems), 375 nM
407of direct primer (CTTTTCTGGTCCTCCGGGTAGG),
408375 nM of reverse primer (CCACCCGGCCCTATTTTA-
409CACCAA), 250 nM of hydrolysis probe (50FAM-
410TTTTCGCAGAACGCCCCTACCCGC-30TAMRA), and
411100 ng of sample DNA. Thermocycling settings consist of
412one hold of 10 min at 95 "C followed by a two-step tempera-
413ture (95 "C for 15 s and 60 "C for 60 s) over 40 cycles. A
414standard curve is established corresponding to a range of
41550,000–0.01 parasites. Sample normalization is performed by
416quantifying a host gene (murine albumin), in 10 μL parallel
417reactions consisting of SYBR Green ROX Mix 2!, 100 nM of
418forward primer (CCATTGGTGAGACCAGAGGT), 100 nM
419of reverse primer (GAGGCAGGCAGCTTTATCAG), 100 ng
420of DNA, and the same thermal profile used for parasite quanti-
421fication. A calibration curve ranging from 10,000 to 0.1 cells is
422established and parasite load expressed as the number of para-
423sites per million of host cells. For the parasite burden, remove
424the organs from the mice (spleen and liver), weight and
425homogenize in RPMI medium. After cell counting, perform a
426subsequent twofold dilutions, in quadruplicate, in 96-well
427plates, and then incubate at 26 "C for 15 days. Record the
428presence or absence of motile promastigotes in each well.
429Calculate the number of parasites per gram of organ (parasite
430burden) as follows: parasite burden ¼ [(geometric mean of
431reciprocal titer from each quadruplicate cell culture/weight
432of homogenized organ) reciprocal fraction of the homogenized
433organ inoculated into the first well].
4348. AICAR is an AMPK activator, compound c is an AMPK inhibi-
435tor, and SRT1720 is an activator of SIRT1. BMMos from
436Mac-SIRT1 KO mice are treated with AICAR and
437AICAR þ compound c, and BMMos from Mac-AMPK KO
438and Mac-LKB1 KO mice are treated with SRT1720,
439respectively.
4409. In the immunoblot assays, use as a readout the expression of
441total AMPK, AMPK-PThr172, and PGC-1α.
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44210. The procedure warrants a homogeneous distribution of the
443cells under the XF-24 plate surface, decreasing the variability
444among wells.
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